Auspherix Launches with AU$1M in Financing

Auspherix, an Australian early stage anti-infectives company, launched with AU$1m in financing.

The company will in-license intellectual property from the ithree institute at the University of Technology Sydney (UTS), emerging from research led by Professor Ian Charles, Director of the institute together with Dr Dagmar Alber, Senior Research Fellow.

Australia’s Medical Research Commercialisation Fund – managed by Brandon Capital Partners – made the investment, which will be used for a lead optimization program to improve the antibiotic activity and bioavailability of drugs that have been identified through the screening program undertaken at ithree, and to establish initial safety and efficacy data in in vivo models.

Led by Stephen Thompson, Director, Auspherix will seek further investment or industry partnerships to move the novel antibiotics into pre-clinical and clinical development, potentially for broad spectrum use.



Join the discussion